Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Subutex Clear all
Recruiting Not applicable Interventional

Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist Treatment

NCT07342504
View directory record Official record
Conditions
Alcohol Use Disorder, Opioid Use Disorder, Alcohol Use, Opioid Use
Interventions
Brief opioid-informed alcohol treatment
Behavioral
Lead sponsor
University of Notre Dame
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Notre Dame, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Not applicable Interventional Results available

Emergency Department Longitudinal Integrated Care

NCT03699085
View directory record Official record
Conditions
Opioid-use Disorder, Emergency Department
Interventions
ED-LINC
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Results available

Suvorexant for Opioid/Stimulant Co-use

NCT05546515
View directory record Official record
Conditions
Opioid Use Disorder, Stimulant Use Disorder
Interventions
Suvorexant (dual orexin receptor antagonist), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 28, 2026, 3:55 AM EDT
Recruiting Phase 2 Interventional

Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder

NCT06521476
View directory record Official record
Conditions
Central Sleep Apnea Comorbid With Opioid Use
Interventions
Acetazolamide, Placebo
Drug
Lead sponsor
Sanjay R Patel
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

NCT02634788
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 28, 2026, 3:55 AM EDT
Withdrawn Phase 4 Interventional

Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women

NCT04212065
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
buprenorphine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 41 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Not applicable Interventional Results available

OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

NCT04948307
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
OXD01 digital therapy, Standard of Care
Device · Other
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Oceanside, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 4 Interventional

Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)

NCT00798538
View directory record Official record
Conditions
Buprenorphine, HIV, Drug Abuse, Drug Addiction, Drug Dependence, Drug Use Disorders, Drug Use Disorder, Substance Abuse, Opiate Addiction, Substance-related Disorders
Interventions
Services will be provided at one site, Services remain dispersed; i.e., not centralized to one-location or provider.
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 24, 2015 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 4 Interventional Results available

Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment

NCT02032433
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Extended-Release Naltrexone, Buprenorphine-Naloxone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Tarzana, California • Jacksonville, Florida • Rockville, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

NCT04976855
View directory record Official record
Conditions
Healthy Volunteer, Opioid-use Disorder
Interventions
INDV-2000, Placebo, SUBOXONE® sublingual film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 4 Interventional Results available

Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence

NCT00555425
View directory record Official record
Conditions
Opiate Dependence
Interventions
Behavioral: Buprenorphine/naloxone maintenance (Mtn), Behavioral: Buprenorphine/naloxone detoxification (Dtx)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 28, 2026, 3:55 AM EDT
Recruiting Phase 4 Interventional

Low-dose Buprenorphine Initiation for Opioid Use Disorder

NCT05450718
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
buprenorphine-naloxone
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Not applicable Interventional

Pilot Trial of Opioid Taper Support

NCT01883882
View directory record Official record
Conditions
Chronic Non-cancer Pain
Interventions
opioid taper support
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 28, 2026, 3:55 AM EDT
Withdrawn Phase 4 Interventional

Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients

NCT04771689
View directory record Official record
Conditions
Post-operative Pain
Interventions
Buprenorphine/Naloxone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Results available

Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain

NCT03254459
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Buprenorphine Sublingual Spray, Morphine, Oxycodone Hydrochloride, Zofran
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Pasadena, California • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 2 Interventional

Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22

NCT00000240
View directory record Official record
Conditions
Cocaine-Related Disorders, Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
University of Vermont
Other
Eligibility
23 Years to 47 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 28, 2026, 3:55 AM EDT
Withdrawn Not applicable Interventional

Opiate Craving Reduction Study Using Post-detox Patients on Suboxone and Use of TEAS as Adjunctive Treatment

NCT02033746
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Han's Acupoint Nerve Stimulator
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 4 Interventional Results available

Extended Release Naltrexone for Opioid-Dependent Youth

NCT01843023
View directory record Official record
Conditions
Drug Dependence
Interventions
Extended Release Naltrexone, Psychosocial Treatment, Buprenorphine
Drug · Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
15 Years to 21 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 2 Interventional

Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1

NCT00015028
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
23 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nalrexone Facilitated Discontinuation of Buprenorphine

NCT01895036
View directory record Official record
Conditions
Stable Opioid Dependence
Interventions
Naltrexone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 49 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigation of the Pharmacokinetic Profile of CBD

NCT05269706
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Cannabidiol 200mg, Epidiolex, Cannabidiol 400mg, Placebo
Drug
Lead sponsor
Yasmin Hurd
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 28, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

NCT02696434
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naltrexone, Placebo, Buprenorphine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Lauderhill, Florida • Oakland Park, Florida • Winfield, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 28, 2026, 3:55 AM EDT
Not listed Phase 4 Interventional

Buprenorphine and Integrated HIV Care Evaluation

NCT00124358
View directory record Official record
Conditions
Opioid-Related Disorders, HIV Infections, AIDS
Interventions
Buprenorphine, Integrated HIV care and office-based opioid dependence treatment
Drug · Behavioral
Lead sponsor
The New York Academy of Medicine
Other
Eligibility
18 Years and older
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
10
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2007 · Synced Oct 28, 2026, 3:55 AM EDT
Recruiting Phase 4 Interventional

Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery

NCT06949826
View directory record Official record
Conditions
Pain, Postoperative, Ankle Fracture Surgery, Opioid Use Disorder, Opioid Dependence, Opioid Analgesia
Interventions
Buprenorphine Transdermal System, Placebo Patch
Drug
Lead sponsor
Jenna-Leigh Wilson
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 28, 2026, 3:55 AM EDT